Press Resease

Rheumatoid Arthritis Drugs Market by Drug Type (NSAID’s, Analgesics, DMARD’s, Glucocorticoids, Biologics, and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 05-Apr-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3999 Status : Published

Global rheumatoid arthritis drugs market expected to generate around USD 30.7 billion by 2025, at a CAGR of 4.5% between 2019 and 2025. Rheumatoid arthritis (RA) is an autoimmune disorder that leads to pain and inflammation of the joints. It usually affects the joints of wrists, elbows, hands, ankles, and knees.

Description

The report covers a forecast and an analysis of the rheumatoid arthritis drugs market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the rheumatoid arthritis drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the rheumatoid arthritis drugs market on a global level.

In order to give the users of this report a comprehensive view of the rheumatoid arthritis drugs market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug type, distribution channel, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Rheumatoid Arthritis Drugs Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug type launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the rheumatoid arthritis drugs market based on drug type, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some leading players of the global rheumatoid arthritis drugs market include Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Amgen, Inc., UCB S.A., Pfizer, Inc., Bristol-Myers Squibb, AbbVie, F. Hoffmann-La Roche AG, and Novartis International AG.

This report segments the global rheumatoid arthritis drugs market into:

Global Rheumatoid Arthritis Drugs Market: Drug Type Analysis

  • NSAID’s
  • Analgesics
  • DMARD’s
  • Glucocorticoids
  • Biologics
    • TNF-α Antagonists
    • T-Cell Inhibitors
    • CD20 Antigen
    • JAK Inhibitors
    • Anti-IL6 Biologics
  • Others

Global Rheumatoid Arthritis Drugs Market: Distribution Channel Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Sales

Global Rheumatoid Arthritis Drugs Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global rheumatoid arthritis drugs market, 2016-2025 (USD Billion)
    • 2.2. Global rheumatoid arthritis drugs market: snapshot
  •  
  • Chapter 3. Rheumatoid Arthritis Drugs Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global rheumatoid arthritis drugs market drivers: impact analysis
      • 3.2.2. The increasing acceptance of large molecules biologics and biosimilars by rheumatologists
      • 3.2.3. Well-defined reimbursement and regulatory framework in developed regions
      • 3.2.4. Improving treatment options for moderate-to-severe rheumatoid arthritis with second-line therapies
      • 3.2.5. Reorientation of treatment approach from the relief of symptoms to targeted therapy to achieve disease remission
    • 3.3. Market Restraints
      • 3.3.1. Global rheumatoid arthritis drugs market restraints: impact analysis
      • 3.3.2. Treatment accessibility
      • 3.3.3. Patent expiration of blockbuster drugs
      • 3.3.4. Alternative treatment options for rheumatoid arthritis
    • 3.4. Opportunities
      • 3.4.1. Growth opportunities for companies operating in the market
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by drug type
      • 3.6.2. Market attractiveness analysis, by distribution channel
      • 3.6.3. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Rheumatoid Arthritis Drugs Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global rheumatoid arthritis drugs market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Rheumatoid Arthritis Drugs Market - Drug Type Analysis
    • 5.1. Global rheumatoid arthritis drugs market: drug type overview
      • 5.1.1. Global rheumatoid arthritis drugs market revenue share, by drug type, 2018 and 2025
    • 5.2. NSAID's
      • 5.2.1. Global rheumatoid arthritis drugs market for NSAID's, 2016-2025 (USD Billion)
    • 5.3. Analgesics
      • 5.3.1. Global rheumatoid arthritis drugs market for analgesics, 2016-2025 (USD Billion)
    • 5.4. DMARD's
      • 5.4.1. Global rheumatoid arthritis drugs market for DMARD's, 2016-2025 (USD Billion)
    • 5.5. Glucocorticoids
      • 5.5.1. Global rheumatoid arthritis drugs market for glucocorticoids, 2016-2025 (USD Billion)
    • 5.6. Biologics
      • 5.6.1. Global rheumatoid arthritis drugs market for biologics, 2016-2025 (USD Billion)
    • 5.7. Others
      • 5.7.1. Global rheumatoid arthritis drugs market for others, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Rheumatoid Arthritis Drugs Market - Distribution Channel Analysis
    • 6.1. Global rheumatoid arthritis drugs market: distribution channel overview
      • 6.1.1. Global rheumatoid arthritis drugs market revenue share, by distribution channel, 2018 and 2025
    • 6.2. Hospital Pharmacies
      • 6.2.1. Global rheumatoid arthritis drugs market for hospital pharmacies, 2016-2025 (USD Billion)
    • 6.3. Retail Pharmacies
      • 6.3.1. Global rheumatoid arthritis drugs market for retail pharmacies, 2016-2025 (USD Billion)
    • 6.4. Drug Stores
      • 6.4.1. Global rheumatoid arthritis drugs market for drug stores, 2016-2025 (USD Billion)
    • 6.5. Online Sales
      • 6.5.1. Global rheumatoid arthritis drugs market for online sales, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Rheumatoid Arthritis Drugs Market - Regional Analysis
    • 7.1. Global rheumatoid arthritis drugs market: regional overview
      • 7.1.1. Global rheumatoid arthritis drugs market revenue share, by region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
      • 7.2.2. North America rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.2.3. The U.S.
        • 7.2.3.1. The U.S. rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.2.3.2. The U.S. rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.2.4. Canada
        • 7.2.4.1. Canada rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.2.4.2. Canada rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
      • 7.3.2. Europe rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.3.3. U.K.
        • 7.3.3.1. U.K. rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.3.3.2. U.K. rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.3.4. Germany
        • 7.3.4.1. Germany rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.3.4.2. Germany rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.3.5. France
        • 7.3.5.1. France rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.3.5.2. France rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.3.6. Rest of Europe
        • 7.3.6.1. Rest of Europe rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.3.6.2. Rest of Europe rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
      • 7.4.2. Asia Pacific rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.4.3.2. China rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.4.4.2. Japan rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.4.5.2. India rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.4.6. Rest of Asia Pacific
        • 7.4.6.1. Rest of Asia Pacific rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.4.6.2. Rest of Asia Pacific rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
      • 7.5.2. Latin America rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.5.3.2. Brazil rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 7.5.4. Rest of Latin America
        • 7.5.4.1. Rest of Latin America rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
        • 7.5.4.2. Rest of Latin America rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa rheumatoid arthritis drugs market revenue, by drug type, 2016-2025 (USD Billion)
      • 7.6.2. The Middle East and Africa rheumatoid arthritis drugs market revenue, by distribution channel, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Company Profiles
    • 8.1. Boehringer Ingelheim GmbH
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Regeneron Pharmaceuticals, Inc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Johnson & Johnson
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Amgen, Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. UCB S.A.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Pfizer, Inc.
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Bristol-Myers Squibb
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. AbbVie
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. F. Hoffmann-La Roche AG
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Novartis International AG
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments

Methodology

Free Analysis

Rheumatoid arthritis (RA) is an autoimmune disorder that leads to pain and inflammation of the joints. It usually affects the joints of wrists, elbows, hands, ankles, and knees. Some type of RA also affects the respiratory and cardiac systems, which is known as a systemic disease. These usually affect the geriatric population base, and the prevalence is high among the female population as compared to males. RA is also known as a musculoskeletal disease, as it causes deformity and severe pain in some areas of the musculoskeletal system. In some cases, redness, warmth, and swelling in the affected areas are also exhibited.

The presence of biologics and biosimilars, the rising prevalence of the disease, and established regulatory guidelines are likely to boost the rheumatoid arthritis drugs market growth globally. As per the Arthritis Foundation, around 64% population aged 65 or above is likely to suffer from arthritis in the U.S. The incidence of RA widely differs in different regions, i.e., higher rates are observed among the American populations while lower rates in the Asian countries. As per the CDC, the prevalence of RA in the U.S. is approximately 0.6% of the total population. Generally, RA affects twice the number of women as compared to men. According to the WHO, the RA prevalence varies between 0.3% and 1% and is more prominent in developed countries. The rising disease remittance therapies awareness and increasing healthcare expenditure in developed countries are likely to further promote rheumatoid arthritis drugs market growth globally in the future.

Global Rheumatoid Arthritis Drugs Market

The global rheumatoid arthritis drugs market is segmented on the basis of drug type and distribution channel. Based on drug type, the market for rheumatoid arthritis drugs is classified into NSAID’s, analgesics, DMARD’s, glucocorticoids, biologics, and others. The biologics segment further includes TNF-α antagonists, T-cell inhibitors, CD20 antigen, JAK inhibitors, and anti-IL6 biologics. On the basis of the distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, drug stores, and online sales.

By region, North America is likely to dominate the rheumatoid arthritis drugs market globally in the future. The U.S. is at the forefront in terms of growth in this region. The rheumatoid arthritis drugs market in the Asia Pacific region is estimated to witness a high growth rate in the years ahead, owing to the rising healthcare expenditure and low manufacturing costs in India and China have resulted in the rise of production facilities which is attracting more pharmaceutical and biotechnological key players to this region.

Some leading players of the global rheumatoid arthritis drugs market include Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Amgen, Inc., UCB S.A., Pfizer, Inc., Bristol-Myers Squibb, AbbVie, F. Hoffmann-La Roche AG, and Novartis International AG.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social